Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANDRODERM vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
FDA-approved: testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). Off-label: delayed puberty in males, female-to-male transgender hormone therapy.
Management of mild to moderate pain,Reduction of fever
Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life is approximately 10–100 minutes (rapid), but due to transdermal absorption, effective half-life is extended to about 8–10 hours after patch application.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Testosterone is metabolized primarily in the liver via CYP3A4 and CYP2C9 isoenzymes, as well as by 5α-reductase to dihydrotestosterone (DHT) and by aromatase to estradiol.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Approximately 90% of testosterone metabolites are excreted in urine as glucuronide and sulfate conjugates; 6% are excreted in feces via bile.
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Approximately 98–99% bound: primarily to sex hormone-binding globulin (SHBG, ~40%) and albumin (~60%).
10-25% bound to albumin at therapeutic concentrations.
Volume of distribution is approximately 0.2–0.8 L/kg, reflecting distribution into steroid-sensitive tissues and binding proteins.
0.8-1.0 L/kg; suggests distribution into total body water.
Transdermal bioavailability is approximately 10–15% of the nominal dose (based on 24-hour application), with interindividual variability due to skin permeability.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No specific dose adjustment recommended for renal impairment. Use with caution in patients with severe renal impairment due to potential fluid retention.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use with caution and monitor liver function; no specific dose adjustment guidelines.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Not indicated for use in pediatric patients. Safety and efficacy have not been established in children <18 years.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
Initiate at 2.5 mg once daily in elderly patients due to increased risk of adverse effects, particularly prostatic hyperplasia and cardiovascular events. Monitor serum testosterone levels and adjust as needed.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
WARNING: Cardiovascular risk - Increased risk of myocardial infarction, stroke, and cardiovascular death has been reported with testosterone replacement therapy. Only use in men with confirmed hypogonadism.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Elderly patients and those with known cardiovascular risk factors should be monitored for cardiovascular events.,May exacerbate sleep apnea in predisposed individuals.,Can cause erythrocytosis; monitor hematocrit.,May accelerate growth of prostate cancer and benign prostatic hyperplasia; monitor prostate-specific antigen (PSA).,Monitor for signs of virilization in women if used off-label.,Possible hypercalcemia in immobilized patients.
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Men with carcinoma of the breast or known or suspected carcinoma of the prostate.,Women who are pregnant or may become pregnant (risk of virilization of fetus).,Hypersensitivity to testosterone or any component of the product.,Severe renal or hepatic impairment (risk of fluid retention).
Hypersensitivity to acetaminophen or any component of the formulation
No known food interactions. Take with or without food.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, clitoromegaly) with androgen exposure during critical period of genital differentiation (weeks 8-12). Second and third trimesters: risk of clitoral enlargement, advanced bone age, and potential long-term behavioral effects. Male fetuses may experience premature sexual development. No adequate studies; USP pregnancy category X.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Testosterone is excreted into human milk; M/P ratio not established. Potential for virilization of female infants and early puberty in male infants. Risk of suppression of maternal lactation (androgen-induced decrease in prolactin). Contraindicated during breastfeeding; alternative therapies recommended.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
Androderm is contraindicated in pregnancy; no dose adjustments applicable. If therapy is necessary for maternal hypogonadism, discontinue immediately upon pregnancy recognition. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are irrelevant due to contraindication. Do not dose in pregnancy.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Apply to clean, dry, intact skin on the abdomen, thighs, upper arms, or back. Rotate application sites to minimize skin reactions. Do not apply to genitals or scrotum. Avoid showering or swimming for at least 3-4 hours after application to ensure absorption. Monitor serum testosterone levels 14 days after starting therapy or dose adjustment, drawn in the morning before application. Use with caution in patients with known or suspected prostate cancer or breast cancer. Warn patients about the risk of transfer to women and children through skin contact; cover application site with clothing or wash skin before contact.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Apply the gel to clean, dry, intact skin once daily in the morning.,Rotate application sites to prevent skin irritation.,Avoid direct skin contact with women and children; wash hands thoroughly after application and cover the site with clothing.,Do not apply to the genitals or scrotum.,Do not shower or swim for at least 3-4 hours after application.,Monitor for signs of skin irritation, such as redness or itching.,Report any swelling of the ankles, difficulty breathing, or changes in mood or sleep.,Keep the medication away from children and pets.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANDRODERM vs INJECTAPAP, answered by our medical review team.
ANDRODERM is a Androgen that works by Testosterone is an androgen receptor agonist; it binds to androgen receptors, leading to changes in gene expression that promote male secondary sexual characteristics and maintain libido, muscle mass, and bone density.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANDRODERM and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANDRODERM is: Apply one 2.5 mg or 5 mg transdermal system to clean, dry, intact skin on the abdomen, upper arms, or thighs once daily, preferably in the morning. Starting dose is 5 mg daily; adjust based on serum testosterone levels.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANDRODERM and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANDRODERM is classified as Category C. Androderm (testosterone) is contraindicated in pregnancy due to virilization of female fetus. First trimester: high risk of pseudohermaphroditism in female fetuses (labial fusion, . INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.